key: cord-0285023-030pz1g3
authors: Liao, S.-Y.; Gerber, A. N.; Zelarney, P.; Make, B.; Wechsler, M. E.
title: Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world data analysis
date: 2021-08-05
journal: nan
DOI: 10.1101/2021.08.03.21261483
sha: 7bf57f493db6113c0ecccf9f2ec7784949ca1c54
doc_id: 285023
cord_uid: 030pz1g3

This study is to investigate whether certain medical conditions may impair antibody response to the mRNA vaccines. In this unique study, participants were drawn from patients in National Jewish Health, a pulmonary specialty outpatient clinic.Our study highlights fact that 26% of our patients (n=226) who had spike protein ab measured at least 14 days post 2nd vaccine had negative spike protein ab testing. We found interstitial lung disease (ILD) to be an independent risk factor for impaired antibody response. While the exact antibody level that confers protection against SARS-CoV-2 is unknown and there may be other non-B cell-mediated protection (e.g. T cell-mediated), our study raises concerns that SARS-CoV-2 vaccination may not result in protective immunity in all populations and may have implications for some as masking and distancing strategies are abandoned.

medical conditions on antibody response. This study was to use real-world data to evaluate whether individuals with chronic medical conditions have impaired antibody response to SARS-CoV-2 mRNA vaccines.

Methods: We used National Jewish Health electronic medical records to identify patients who received 2 doses of SARS-CoV-2 mRNA vaccines between December 16, 2020-July 24, 2021, and had a spike IgG antibody results at least 14 days after the second dose. These tests were clinically ordered by individual physicians at our subspecialty academic medical center focused on chronic respiratory and immune disorders. Anti-SARS-CoV-2 ELISA (EUROIMMUN US, New Jersey) with a recombinant S1 domain of the spike protein was used to measure IgG antibodies to SARS-CoV-2 spike protein. The ratio of the sample optical density (OD) to the OD of a calibration provided with the kit was interpreted as positive (≥0.8) or negative (<0.8) (5) . Medical conditions were based on physician diagnosis ICD-10 codes; medications were defined as in a previous study (6) . A multivariate logistic regression model was used to identify clinical characteristics associated with the spike IgG protein being negative. Due to the small sample size, overlap propensity score weighting (7) was used to analyze medication effects.

Results: We identified 226 patients (mean age 62 years; 62% female) who received 2 doses of mRNA vaccines and had antibody testing (Table) . BNT162b2 (Pfizer-BioNTech) was administered to 66% of the patients and 34% received mRNA-1273 (Moderna). At a mean (standard deviation) of 62 (35) days, range 14-161 days, after dose 2, 26% had no antibody detected. Negative antibody responses were found in 47 patients receiving the BNT162b2 Eight patients had documented COVID-19 infection before the vaccination. The percentages of patients without antibodies detected ranged from 14% in chronic obstructive pulmonary disease to 53% in congestive heart failure (CHF) ( Table) . Multivariate logistic regression ( Figure) showed that interstitial lung disease (ILD) (OR 0.21, 95% CI 0.08-0.56), CHF (OR 0.26, 95% CI . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.03.21261483 doi: medRxiv preprint 0.07-0.98), and use of biologics (anti-IL-5, -IL-6, -IL-12/23, -IL-17, -IgE, -CD20, and -TNF-α inhibitors) /JAK inhibitors (OR 0.17, 95% CI 0.07-0.46) are significant risk factors for negative antibody response adjusted for age, gender, vaccine types, days after vaccination, other medication use and comorbidities. Using overlap propensity score weighting, biologic/JAK inhibitor use is associated with impaired antibody response (OR 0.79, 95% CI 0.68-0.91). We Discussion: It is critical to recognize that vaccination may not necessarily confer immunity, at least as assessed by commercially available spike protein antibody tests, particularly in patients with certain chronic medical conditions and certain medication use. In our patients (79% with chronic pulmonary diseases), 26% had no antibody detected > 14 days after the second dose of mRNA vaccines. While these data show that all vaccinated individuals may be at risk for impaired antibody production, we found that CHF, ILD (independent of their medication use), and biologic/JAK inhibitor use (especially rituximab) are independent risk factors for impaired antibody response. The effect of rituximab use is consistent with a previous study (8) . While the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.03.21261483 doi: medRxiv preprint exact antibody level that confers protection against SARS-CoV-2 is unknown and there are other markers of B cell and T cell-mediated protection(9), a recent study showed that among fully vaccinated health care workers, the occurrence of breakthrough COVID-19 infection was correlated with the titer of antibodies (3) . We have yet to observe the occurrence of COVID-19 infections in these patients with negative antibody responses. However, given the relatively low prevalence of COVID-19 infection in our region, the relatively short time since vaccines were administered, the lack of rigorous follow-up to assess infections, and the recommendations by . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.03.21261483 doi: medRxiv preprint

COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis

Breakthrough Covid cases: Data shows how many vaccinated Americans have tested positive

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases

Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

The study was approved by the National Jewish Health Institutional Review Board. The authors would like to thank Joy Zimmer for her help with the electronic health record data query.Author Contributions: Dr. Liao had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All

80 (36) 56 (32) * primary medical conditions and relevant medications † Number and (%) of patients by row ‡ Biologics: Anti-IL-5, -IL-6, -IL-12/23, -IL-17, -IgE, -CD20, and -TNF-α inhibitors COPD: chronic obstructive pulmonary disease; ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers